Table 1.
Pretreatment demographic, biochemical, serological, molecular and histological characteristics of 55 patients receiving retreatment with IFN‐α2a with and without amantadine sulphate
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.